How Antibodies Block VLA-4 to Treat Inflammatory Diseases

This patent describes antibodies, which are immune system proteins, designed to specifically attach to and block a target protein called VLA-4, which is involved in inflammation and immune responses.

What it covers

This invention focuses on antibodies and their fragments that are designed to bind to alpha-4, a component of the VLA-4 protein. VLA-4 is a cell surface protein that helps immune cells stick to blood vessel walls and move into tissues, a process central to inflammation. By binding to alpha-4, these antibodies aim to prevent immune cells from migrating, thereby reducing inflammation. For example, in conditions like multiple sclerosis, immune cells incorrectly attack nerve tissue; an antibody targeting VLA-4 would aim to stop these cells from reaching the brain and spinal cord.

What it doesn't cover

• —Does not cover small-molecule drugs that block VLA-4, as the invention specifically relates to antibodies and their fragments.
• —Does not cover antibodies that target other cell adhesion molecules not related to the alpha-4 subunit of VLA-4.
• —Does not cover gene therapies or cell therapies aimed at modulating VLA-4 expression or function.
• —Does not cover diagnostic methods using VLA-4 binding agents, as the focus is on therapeutic antibodies.

The clever bit

The novelty lies in designing antibodies that precisely recognize and bind to the alpha-4 subunit of VLA-4. This specific binding can effectively disrupt the VLA-4 protein's function, preventing immune cells from migrating to sites of inflammation without broadly suppressing the entire immune system.

Why it matters

VLA-4 is a critical target in treating various autoimmune and inflammatory diseases, including multiple sclerosis and Crohn's disease. Drugs that block VLA-4 have demonstrated significant clinical benefits by preventing immune cells from causing damage in affected tissues. This type of invention contributes to the ongoing development of more effective and targeted therapies for chronic inflammatory conditions.

Real-world examples

• 1.Tysabri (natalizumab) for multiple sclerosis and Crohn's disease
• 2.Vedolizumab (Entyvio) for ulcerative colitis and Crohn's disease
• 3.Antibody therapies for inflammatory bowel disease